Bilcare Ltd · NSE:BI
Bilcare — Investor Presentation (January 2010)
21 slides from Bilcare's investor presentation, January 2010
Slide 1: Business Overview
Business Overview
Slide 2: Corporate Overview
Corporate Overview P va r 7 5 i Ww a Bilcare’.
Slide 3: Corporate Overview – Bilcare Limited
Corporate Overview – Bilcare Limited Leading provider of research-driven packaging solutions solely-focused on pharmaceutical industry ▬ Founded in 1994 and based in Pune, India with global presence ▬ Manufactures packaging materials to significantly enhance function, physical efficiency and safety
Slide 4: Corporate Overview – Bilcare Singapore
Corporate Overview – Bilcare Singapore Singapore subsidiary, Bilcare Singapore founded to consolidate our international operations ▬ Manufacturing facilities in operation in Singapore, the US and the UK, & regional sales offices spread across Europe and Latin America Provides solutions across the ph
Slide 5: Corporate Structure
Corporate Structure Bilcare Bilcare India India 100% 50% Bilcare Bilcare Singapore Singapore International International Labs Labs 100% 100% 100% 100% Bilcare Bilcare GmbH GmbH Bilcare Bilcare US US Bilcare Bilcare UK UK Bilcare Bilcare Brazil Brazil (Germany) (Germany) 100% 100% Bilcare Bilcare Cli
Slide 6: Bilcare International Presence
Bilcare International Presence USA UK (DHP) Germany Clinical trial services facility Clinical trial services facility Currently sales office 14 acre FDA & DEA approved site MHRA approved site Upcoming greenfield facility in Films & foils secondary production 42 employees Europe 179 employees 6-8 mon
Slide 7: Major Global Customers
Major Global Customers | U> NOVARTIS AstraZeneca A ‘s SP. covon sanofi aventis ial RANBAXY Pfizer, TY Dr. Repos LABORATORIES LIMITED Wyeth Bilcare’ .;
Slide 8: Pharmaceutical Value Chain
Pharmaceutical Value Chain Drug Formulation Clinical Trials Manufacturing Market Discovery Development & Packaging Research Services Clinical Services Packaging Materials Formulation Batch Manufacturing Poly films Analytical Primary Packaging Aluminium Foils Stability Studies Labeling Paper Composit
Slide 9: Pharma Packaging Research
Pharma Packaging Research Bilcare’ =.
Slide 10: Market Landscape
Market Landscape Market size – estimated to increase from $4 Billion (2007) to $6 Billion (2010) Challenges for Pharma industry are becoming more complex ▬ Global supply chain ▬ Pharma specific requirements ▬ Boardroom challenges to combat lack of growth in the industry Vendors continue to remain co
Slide 11: Pharma Packaging Challenges
Pharma Packaging Challenges 5C Brand Challenges Compliance Compliance Counterfeit Counterfeit Communication Communication Convenience Convenience Cost Cost $150 $150 Billion Billion $50 $50 Billion Billion ++ Accidental Accidental Senior Senior Over-packed Over-packed revenue revenue loss loss brand
Slide 12: Pharma Packaging Research
Pharma Packaging Research Products Comprehensive range of innovative packaging materials – films & foils: ▬ Scientific optimization of drugs ▬ Maximize shelf-life ▬ Increased product stability PVC is most ▬ Enhanced speed to market common resin for core layer ▬ Protection against counterfeits Packag
Slide 13: Competitive Value Chain – No Clear Competitor
Competitive Value Chain – No Clear Competitor Food Cosmetics FMCG etc Pharma Stationary Credit Card Food etc Pharma Laminates Laminates Foils Coating Coils Films Ingots Resin Bauxite ALCAN Aluminium-focused EVC (INEOS) Polymer-focused 13
Slide 14: Global Clinical Research Management
Global Clinical Research Management 14
Slide 15: Market Overview
Market Overview In-house clinical services market currently @ $1 Billion – untapped potential market for outsourcing Competition – companies doing outsourced clinical services ▬ Fisher - $300 million in revenues (total revenues $7 billion) ▬ Aptuit - $150 million in revenues ▬ Almac - $100 million i
Slide 16: Clinical Trials
Clinical Trials Clinical trials are becoming global in nature and increasingly complex in protocol design Bilcare’s clinical trial services provides end-to-end clinical supplies management services including: ▬ Protocol design ▬ Regulatory compliance & patient safety ▬ Batch manufacturing ▬ Packagin
Slide 17: Clinical Research Challenges
Clinical Research Challenges Challenges Challenges Speed of trials ▬ 1 week loss = $20 Mn for $1 Bn new drug Accuracy of data ▬ Retrial can delay launch by 1-2 years Global reach ▬ Patient population in US/ Europe ageing Reliability ▬ IPR ▬ World-class QA Systems Competent & Focused Outsourced Partn
Slide 18: Bilcare Solutions
Bilcare Solutions Biotech & small size full-service contracts Leverage India (for Asian trials & cost) Global reach Leverage IT technology Effect High growth in volume & margin First mover advantage in Asia Leadership position by 2010 18
Slide 19: Business Strategy
Business Strategy . _ f , A . J 5 I Ww # © Bilcare’ ;»
Slide 20: Bilcare Strategy
Bilcare Strategy Integration into the pharmaceutical value chain at multiple points ▬ Major pharmaceutical companies are getting attracted to Bilcare’s full-service capabilities and undergoing audit processes Technology and research driven customized solutions ▬ Successful commercialization of solut
Slide 21: Technology & Research
Technology & Research Transforming products & services company to IPR IPR an IPR company Research focus symbolizes the drive Technology Technology Unique technologies will be acquired in Acquisition Acquisition synergy with strategy plan Application Application Research Research Many scientists are